24/7 Market News Snapshot 20 Jun 2024 – Tempest Therapeutics, Inc. Common Stock (NASDAQ: TPST)

June 20, 2024 7:10

Press Release

DENVER, Colo., 20 June, 2024 (247marketnews.com) – (Nasdaq:TPST) are discussed in this article.
Tempest Therapeutics, Inc. Common Stock (TPST) has surged impressively by 41.65% in the pre-market session, reaching $4.039 from a previous close of $2.85, with a substantial trading volume of 10.6 million shares. This bullish momentum signifies a potential breakout for TPST, attracting investors with promising returns. Simultaneously, Tempest Therapeutics, Inc. (Nasdaq:TPST) has unveiled encouraging results from its global Phase 1b/2 clinical trial. The study highlighted the substantial progress of TPST-1120, Tempest’s PPAR⍺ antagonist, in combination with atezolizumab and bevacizumab, showcasing a notable six-month improvement in median overall survival for patients with unresectable or metastatic hepatocellular carcinoma. This breakthrough underscores Tempest’s innovative approach to oncology therapy, garnering significant recognition within the medical community. The company’s dedication to pioneering novel treatment solutions that integrate targeted and immune-mediated mechanisms has set a new benchmark in combating complex diseases like HCC. As a leader in the oncology domain, Tempest Therapeutics continues to redefine treatment standards and drive transformative patient outcomes through its groundbreaking therapeutic advancements.

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 Market News, Inc Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.